

# Baxter

## TherMax

BLOOD WARMER

## MAXIMISE YOUR TREATMENT **ACCURACY** AND SYSTEM **PERFORMANCE**

with the **TherMax** blood warmer powered by the **PrisMax** system

The **TherMax** blood warmer brings an innovative approach to CRRT blood warming, allowing clinicians to set and achieve blood warming targets in a safe and simple manner. The **TherMax** blood warmer is controlled through the intuitive user interface of the **PrisMax** system and delivers effective blood warming for a range of therapies through one device.<sup>1</sup>

- **EFFICIENT BLOOD WARMING** to maintain patient blood temperature during CRRT therapy
- **PRECISE CONTROL** of return blood temperature helps to reduce risk of hypothermia
- **EASY WARMER MANAGEMENT** through the **PrisMax** system user interface

TherMax Blood Warmer	Fluid Warming
Heats blood directly	Heats fluid, with diminished control of blood temperature
Independent from therapy flow rates	Dependent upon therapy flow rate to achieve target warming levels
Continuous warming	Blood is not warmed during therapy interruptions
Avoids precipitation caused by warming of bicarbonate solutions	Additional risk of precipitating events and de-gassing caused by warming of bicarbonate solutions
Automatically adjusts heating based on estimated return blood temperature to achieve prescribed warming target	Can only set fluid warming temperatures without the ability to monitor or adjust return blood temperature



### Intelligent Warmer

The **TherMax** blood warmer uses a bi-directional connection with the **PrisMax** system to meet warming targets. This enables the warmer to continuously respond to changing treatment parameters by automatically adjusting heating to meet the prescribed return blood temperature. Once the prescription is entered, no further management or adjustments are needed.<sup>1</sup>



Advanced Safety Features

The **TherMax** blood warmer includes a number of patient safety features to control temperature, detect leaks, and to ensure the correct setup:<sup>1</sup>

- Automatic adjustment of heating during therapy interruptions to ensure blood is not overheated.
- Reduces risk of thermal haemolysis by limiting the maximum outlet temperature to 42 °C.<sup>2</sup>
- Warmer switches off in case of blood pump stop or communication failure.
- Alarm system integrates with the **PrisMax** system to notify the user if unexpected conditions are encountered such as leakages of the warmer bag or instances in which patient warming cannot be fully delivered due to external factors.



New Design

TherMax Device

- Dry heat is delivered by plates
- Controlled via the **PrisMax** system’s interface
- Opens for easy cleaning

TherMax Disposable

- Limited extracorporeal blood volume (27 ml)
- Reduction of clotting by:
  - Patented design of bends and turns
  - Optimised design for inlet and outlet areas

Specifications

Physical Dimensions		Heating Specifications	
Weight	3.3 kg	Selectable set point temperatures	35 °C to 38 °C (the temperature setting is controlled by the <b>PrisMax</b> system)
Height	Approx. 135 mm	Accuracy of temperature (patient return temperature controlled by the <b>PrisMax</b> system)	±0.8 °C at steady state for blood flow rates >150 ml/min
Width	Approx. 160 mm		±1.5 °C at steady state for blood flow rates between 50 and 150 ml/min.
Depth	Approx. 350 mm	Maximum plate temperature	Heater plates are controlled to 45.5 °C
Set Compatibility		Excessive temperature cut off	Safety cutoff at 46.8 °C
Compatible with all <b>Prismaflex</b> sets excluding HF20		Heating up time (22 °C to 45 °C)	~5 min
For patients with low body weight, sleeve warmers are indicated.			

For more information, please speak with a Baxter representative.

For safe and proper use of products mentioned herein, please refer to applicable Operators Manual or Instructions for Use

References  
1. Baxter - TherMax Operators Manual. AW7006 Rev A 2018;Sep.  
2. Pouchoulin D. HELIOS/CALIDUS Thermax heating coverage - final estimate for initial release. DPN 18.13 Heating coverage from Thermax. Région de Lyon, France: Baxter International Inc.; 2018.